Vascular BioSciences Announces Research Results Demonstrating Improved PH and Sepsis Survival
CEO of Vascular BioSciences, David Mann, makes connection between current research and COVID-19 applications
Vascular BioSciences releases Abstract A7856 – Cyclic CAR Peptide Modulates the Effects of Treprostinil and Macitentan in Experimental Pulmonary Hypertension.1 This research was conducted in collaboration with Dr. Paul B. Yu, Dr. Aaron Waxman and colleagues at Brigham and Woman's Hospital and at Harvard Medical School, both in Boston, Massachusetts.
Vascular BioSciences also presented important new findings on a novel sepsis treatment in Abstract A2595 – Improved Survival After Surgical Sepsis in Rats Using a Novel Vascular Homing Peptide to Target Endothelial Delivery of Hydrocortisone.2This research was conducted in collaboration with Dr. Nadir Yehya and Dr. Scott Weiss from Children's Hospital of Philadelphia in Philadelphia, Pennsylvania.
These results have particular relevance to the pressing need to develop effective COVID-19 therapies since sepsis and septic shock are the end stage clinical manifestations of COVID-19, driving patient mortality. Data show that 100% of COVID-19 non-surviving patients develop sepsis, as opposed to 42% of survivors.3
"Research on our CAR peptide has shown that it has the potential to be an extremely effective therapy for sepsis by targeting corticosteroids to the damaged tissue," said Mr. Mann. "We are hopeful that these findings can be translated to the clinic to help lower the mortality of sepsis and COVID-19. We are working hard to help provide more effective therapies for patients with COVID-19 that develop sepsis."
About Vascular BioSciences
Vascular BioSciences, a biomedical company with operations in California and North Carolina, provides targeted solutions for serious diseases in order to enhance and prolong human life.
For more information about VBS is available at www.vascularbiosciences.com
For more information, please contact firstname.lastname@example.org
3. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).
Page Updated Last on: Jun 04, 2020